We are excited to announce our participation in the Medlab Middle East Medical Expo & Conference 2025 in Dubai. Wuhan YZY Medical Science and Technology Co., Ltd. (YZY Med) will showcase its comprehensive range of advanced diagnostic products, including qPCR reagents, FISH probes, automatic devices, circulating tumor cell separation technologies, and staining devices. We invite all partners and potential buyers to visit our booth at Z1.A36 from February 3rd to 6th.
As a leader in precision and personal diagnostics, our innovations support enhanced patient outcomes, particularly in cardiovascular and oncological care. We look forward to fruitful collaborations and discussions with you at the expo. Let us advance the future of individualized medical diagnostics together. Visit us to explore opportunities and partnerships that could benefit your organization.
- Product Line and Strategic Advantages
1.1 Circulating Tumor Cell (CTC) Separation Platform
YZY Med leads the Chinese market with its CTC separation technology, a crucial tool in liquid biopsy technology. The CTCBIOPSY® system employs immunomagnetic bead sorting to enrich circulating tumor cells, enabling detailed flow cytometry and fluorescence quantitative PCR analyses. This system is instrumental in monitoring cancer recurrence, high-risk screening, and providing auxiliary diagnoses across all solid tumor types.
Devices: Offerings CTC A10 Separator for single-channel assays and the D200 Separation and Staining all-in-one system.
Consumables: Include patented CTC Cell Filters and corresponding staining kits.
1.2 Clinical Level qPCR-based Kits
These kits facilitate tumor companion and pharmacogenomics diagnostics, crucial in personalized treatment strategies. The companion diagnostic (CDx) kits target genes such as EGFR, BRAF, KRAS, NRAS, PIK3CA, ROS1, and ALK, essential in treating specific cancer types. The pharmacogenomics (PGx) kits analyze genetic variations affecting drug metabolism, including medications for hyperlipidemia, hypertension, and gout, thereby optimizing drug efficacy and minimizing adverse effects.
1.3 Fluorescence In Situ Hybridization (FISH) Tests
YZY Med offers complete FISH solutions, including over 140 FISH probes and kits for sample pre-processing, critical for assessing genomic abnormalities and cancer progression. Their semi- or fully-automatic FISH instruments streamline the process, enhancing the precision and reliability of diagnostics. FISH tests cover genetic detection for cancers like breast cancer, leukemia, and various lymphomas.
- Achievements and Global Expansion
2.1 Market Leadership and Achievements
YZY Med enjoys a dominant position in the Chinese pharmacogenomics and companion diagnostics markets, backed by significant achievements including over 450 million in sales revenue across more than 600 hospitals. Their robust R&D efforts have led to over 160 licensed diagnostic products and numerous patents, reinforcing their competitive edge. Such advancements underscore the company’s commitment to offering high-quality clinical-level and research-use-only (RUO) diagnostic solutions.
2.2 Global Impact and Strategic Collaborations
The company’s products are utilized globally, impacting hospitals and research institutions worldwide. Strategic collaborations and continued investment in R&D ensure YZY Med remains at the forefront of precision diagnostics. This global reach supports their vision of advancing personalized medicine, consistently setting new benchmarks in the industry.
- Opportunities and Future Directions
YZY Med’s global influence extends through strategic collaborations and partnerships, which are pivotal in advancing personalized medicine. We offer a diverse array of cooperation models, including OEM, ODM, and license-out opportunities for our existing products. Additionally, we provide tailored solutions to meet specific customer needs, featuring custom manufacturing, qPCR and FISH probe design, as well as comprehensive test development services. These flexible collaboration modes demonstrate our commitment to innovation and adaptability, ensuring that we meet the unique requirements of our partners and contribute significantly to global healthcare advancements. Through these initiatives, YZY Med remains at the forefront of precision diagnostics, fostering impactful and meaningful international partnerships.
